• © Baliopharm AG 2024
• Imprint
• Privacy policy
• Cookie policy
• Terms of use
• Sitemap

Baliopharm / Strategy

Innovative antibody therapeutics

Baliopharm focuses on the development of innovative antibody and antibody derived therapeutics for the treatment of chronic liver diseases like Nonalcoholic steatohepatitis (NASH), autoimmune diseases like rheumatoid arthritis, Morbus Crohn and multiple sclerosis and for the treatment of cancer. Our drug candidates have been designed to exhibit increased target selectivity, thereby bearing the opportunity of superior efficacy and safety compared to currently available treatment options.  

The development of Baliopharm´s lead compounds, the anti-TNF antibodies ATROSAB and ATROSIMAB, are pursued for NASH and potentially other chronic liver diseases. 

Beyond that, Baliopharm develops these compounds as well as Novotarg for other autoimmune and tumor diseases. It is the intention of Baliopharm to develop these drug candidates at a maximum up to phase II proof of concept in patients and to partner afterwards. For smaller indications and selected markets, Baliopharm may consider developing its drug candidates up to market launch.